Immune recovery in tumor microenvironment of TP53 -mutated AML following venetoclax combination therapy

  1. Kohei Yamada
  2. Jun Ando
  3. Yoshiki Furukawa
  4. Midori Ishii
  5. Shintaro Kinoshita
  6. Kota Tachibana
  7. Yoko Azusawa
  8. Yoko Edahiro
  9. Yutaka Tsukune
  10. Hajime Yasuda
  11. Tomoiku Takaku
  12. Yasuharu Hamano
  13. Makoto Sasaki
  14. Masanori Nojima
  15. Miki Ando
Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Highlights

  • Single-cell RNA sequencing of bone marrow from TP53-mutated AML patients showed a decrease in cells expressing anti-apoptotic genes like BCL2 and MCL1 after venetoclax and azacitidine treatment.

  • Immune cells increased both in number and in gene expression levels associated with cytotoxicity post venetoclax combination therapy, verifying immune recovery.

  • Residual AML cells expressed CD47 and CLL1, suggesting a role for ancillary treatment targeting antigens expressed on residual TP53 -mutated AML cells.

    • The BCL-2 inhibitor venetoclax combined with the hypomethylating agent azacitidine or with low-dose cytarabine significantly improves response rates and overall survival (OS) for newly diagnosed unfit and relapsed / refractory (R/R) acute myeloid leukemia (AML) patients. We retrospectively analyzed our experience with venetoclax combination therapy in 41 unfit AML patients (23 untreated, 18 R/R). Overall response rates were 78.3% for untreated patients and 61.1% for R/R patients. TP53 alterations were observed in 13 patients (31.7%) and were identified as an independent predictor of poor outcome (p=0.0008). We further conducted single-cell RNA sequencing in bone marrow, sampled before and after venetoclax and azacitidine treatment, of three TP53 -mutated AML patients who achieved complete remission (CR) or CR with incomplete hematologic recovery. After treatment, numbers of cells expressing anti-apoptotic genes such as BCL2 and MCL1 decreased. CD4 T cells, cytotoxic CD8 T cells, and NK cells significantly increased both in number and in levels of gene expression associated with cytotoxicity post-treatment, confirming immune recovery in the tumor microenvironment. Residual AML cells expressed CD47 and CLEC12A (CLL1). These results indicate that venetoclax combination therapy of AML is promising in real-world clinical practice and suggest a role for ancillary treatment targeting antigens expressed on residual AML cells as a therapeutic strategy in TP53 -mutated AML.

    Article activity feed

    1. Version published to 10.1101/2025.05.12.25327414v1 on medRxiv